Atopic Dermatitis: Managing the Itch

  • William S. Farmer
  • Kalyani S. Marathe
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1027)


Atopic dermatitis has a substantial impact on sleep, appearance, psychological well-being, and other qualities of life. The visual appearance of lichenification, cheilitis, hyperpigmentation, ichthyosis, and erythema can be socially stigmatizing, and treatment of these symptoms is challenging. In managing pruritus in patients, practitioners should assess and document pruritus through questionnaires at each routine visit. Initially, practitioners should advise patients to employ non-pharmaceutical treatments such as emollients with wet wraps, elimination of triggers, changing scratching habits, and psychological interventions. If these methods of treatment are not successful or if the disease presentation is severe, pharmacological therapies should be employed. This chapter describes the therapeutic ladder for pruritus in atopic dermatitis and discusses each treatment modality in further detail for practitioners to advise their patients.

First-line topical pharmaceutical agents include topical glucocorticoids and topical calcineurin inhibitors. Second-line topical agents include coal tar, menthol, capsaicin, or doxepin. After the use of topical agents has been exhausted, primary systemic agents can be applied. These include sedating antihistamines, non-sedating antihistamines, oral glucocorticoids, or cyclosporine A. Finally, neuromodulating or immunomodulating agents can be attempted, including SSRI/SNRIs, TCAs, immunosuppressants, neural modulators, and opioid receptor modulators. Outside of pharmacological treatments, phototherapy has been shown to provide a dramatic improvement of pruritus in atopic dermatitis and can be used at any stage of treatment including as a first-line agent.


Pruritus Treatment Anti-Puritus therapeutic ladder 


  1. 1.
    Romeo S. Atopic dermatitis: the itch that rashes. Pediatr Nurs. 1995;21(2):157–63.PubMedGoogle Scholar
  2. 2.
    Ring J, Senter T, Cornell R, Arroyave C, TAN E. Complement and immunoglobulin deposits in the skin of patients with atopic dermatitis. Br J Dermatol. 1978;99(5):495–501. doi: 10.1111/j.1365-2133.1978.tb02016.x.CrossRefPubMedGoogle Scholar
  3. 3.
    Shelley W. The neurohistology and neurophysiology of the itch sensation in man. Arch Dermatol. 1957;76(3):296. doi: 10.1001/archderm.1957.01550210020004.CrossRefGoogle Scholar
  4. 4.
    Ständer S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of μ-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept. 2002;110(1):75–83. doi: 10.1016/s0167-0115(02)00159-3.CrossRefPubMedGoogle Scholar
  5. 5.
    Bastian B, van der Piepen U, Römisch J, Pâques E, Bröcker E. Localization of annexins in normal and diseased human skin. J Dermatol Sci. 1993;6(3):225–34. doi: 10.1016/0923-1811(93)90043-o.CrossRefPubMedGoogle Scholar
  6. 6.
    Johnson H, DeOreo G, Lascheid W, Mitchell F. Skin histamine levels in chronic atopic dermatitis**From the Division of Dermatology, Department of Medicine, Western Reserve University, School of Medicine, Cleveland, Ohio.(Aided by grant from Research and Development Division, Department of the Army, Contract #DA-49-007-MD-573). J Invest Dermatol. 1960;34(4):237–8. doi: 10.1038/jid.1960.38.CrossRefPubMedGoogle Scholar
  7. 7.
    Connelly W, Shenton F, Lethbridge N, Leurs R, Waldvogel H, Faull R, et al. The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol. 2009;157(1):55–63. doi: 10.1111/j.1476-5381.2009.00227.x.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Sonkoly E, Muller A, Lauerma A, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol. 2006;117(2):411–7. doi: 10.1016/j.jaci.2005.10.033.CrossRefPubMedGoogle Scholar
  9. 9.
    Wahlgren C, Hagermark O, Bergstrom R. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol. 1990;122(4):545–51. doi: 10.1111/j.1365-2133.1990.tb14732.x.CrossRefPubMedGoogle Scholar
  10. 10.
    Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov P, et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. Exp Dermatol. 2008;13(9):591. doi: 10.1111/j.0906-6705.2004.0212co.x.CrossRefGoogle Scholar
  11. 11.
    Steinhoff M, Cevikbas F, Ikoma A, Berger T. Pruritus: management algorithms and experimental therapies. Seminars in Cutaneous Medicine and Surgery. 2011;30(2):127–37. doi: 10.1016/j.sder.2011.05.001.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol. 2012;124(1–3):326–31. doi: 10.1159/000053748.CrossRefGoogle Scholar
  13. 13.
    Hong J, Buddenkotte J, Berger T, Steinhoff M. Management of itch in atopic dermatitis. Semin Cutan Med Surg. 2011;30(2):71–86. doi: 10.1016/j.sder.2011.05.002.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Juenger M, Ladwig A, Staecker S, Arnold A, Kramer A, Daeschlein G, et al. Efficacy and safety of silver textile in the treatment of atopic dermatitis (AD). Curr Med Res Opin. 2006;22(4):739–50. doi: 10.1185/030079906x99990.CrossRefPubMedGoogle Scholar
  15. 15.
    Noren P, Melin L. The effect of combined topical steroids and habit-reversal treatment in patients with atopic dermatitis. Br J Dermatol. 1989;121(3):359–66. doi: 10.1111/j.1365-2133.1989.tb01430.x.CrossRefPubMedGoogle Scholar
  16. 16.
    Arnold W. Tar. Clin Dermatol. 1997;15(5):739–44. doi: 10.1016/s0738-081x(97)00018-7.CrossRefPubMedGoogle Scholar
  17. 17.
    Niordson A, Stahl D. Treatment of psoriasis with clinitar cream. A controlled clinical trial. Br J Clin Pract. 1985;39:67–8.PubMedGoogle Scholar
  18. 18.
    Roelofzen J, Aben K, Oldenhof U, Coenraads P, Alkemade H, van de Kerkhof P, et al. No increased risk of cancer after coal tar treatment in patients with psoriasis or eczema. J Investig Dermatol. 2010;130(4):953–61. doi: 10.1038/jid.2009.389.CrossRefPubMedGoogle Scholar
  19. 19.
    Yosipovitch G, Szolar C, Hui X, Maibach H. Effect of topically applied menthol on thermal, pain and itch sensations and biophysical properties of the skin. Arch Dermatol Res. 1996;288(5–6):245–8. doi: 10.1007/s004030050053.CrossRefPubMedGoogle Scholar
  20. 20.
    Dray A. Neuropharmacological mechanisms of capsaicin and related substances. Biochem Pharmacol. 1992;44(4):611–5. doi: 10.1016/0006-2952(92)90393-w.CrossRefPubMedGoogle Scholar
  21. 21.
    Zhang W, Li Wan Po A. The effectiveness of topically applied capsaicin. Eur J Clin Pharmacol. 1994;46(6):517–22. doi: 10.1007/bf00196108.CrossRefPubMedGoogle Scholar
  22. 22.
    Bonnel R, La Grenade L, Karwoski C, Beitz J. Allergic contact dermatitis from topical doxepin: food and drug administration’s postmarketing surveillance experience. J Am Acad Dermatol. 2003;48(2):294–6. doi: 10.1067/mjd.2003.46.CrossRefPubMedGoogle Scholar
  23. 23.
    Sher L, Chang J, Patel I, Balkrishnan R, Fleischer A. PSS1 relieving the pruritus of atopic dermatitis: a meta-analysis. Value Health. 2012;15(4):A249–50. doi: 10.1016/j.jval.2012.03.1345.CrossRefGoogle Scholar
  24. 24.
    Berberian B, Breneman D, Drake L, Gratton D, Raimir S, Phillips S, et al. The addition of topical doxepin to corticosteroid therapy: an improved treatment regimen for atopic dermatitis. Int J Dermatol. 1999;38(2):145–7. doi: 10.1046/j.1365-4362.1999.00505.x.CrossRefPubMedGoogle Scholar
  25. 25.
    Drake L, Fallon J, Sober A. Relief of pruritus in patients with atopic dermatitis after treatment with topical doxepin cream. J Am Acad Dermatol. 1994;31(4):613–6. doi: 10.1016/s0190-9622(94)70225-x.CrossRefPubMedGoogle Scholar
  26. 26.
    Eberlein B, Eicke C, Reinhardt H, Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol. 2007;22(1):73–82. doi: 10.1111/j.1468-3083.2007.02351.x.Google Scholar
  27. 27.
    Inan S, Dun N, Cowan A. Inhibitory effect of lidocaine on pain and itch using formalin-induced nociception and 5′-guanidinonaltrindole-induced scratching models in mice: behavioral and neuroanatomical evidence. Eur J Pharmacol. 2009;616(1–3):141–6. doi: 10.1016/j.ejphar.2009.06.026.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Krutmann J, Diepgen T, Luger T, Grabbe S, Meffert H, Sönnichsen N, et al. High-dose UVA1 therapy for atopic dermatitis: results of a multicenter trial. J Am Acad Dermatol. 1998;38(4):589–93. doi: 10.1016/s0190-9622(98)70123-9.CrossRefPubMedGoogle Scholar
  29. 29.
    Der-Petrossian M, Seeber A, Hönigsmann H, Tanew A. Half-side comparison study on the efficacy of 8-methoxypsoralen bath-PUVA versus narrow-band ultraviolet B phototherapy in patients with severe chronic atopic dermatitis. Br J Dermatol. 2000;142(1):39–43. doi: 10.1046/j.1365-2133.2000.03239.x.CrossRefPubMedGoogle Scholar
  30. 30.
    Nisticò S, Saraceno R, Capriotti E, Felice C, Chimenti S. Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. Photomed Laser Surg. 2008;26(1):14–8. doi: 10.1089/pho.2007.2116.CrossRefPubMedGoogle Scholar
  31. 31.
    Lewis T. The blood vessels of the human skin and their responses. Arch Dermatol. 1928;18(6):991. doi: 10.1001/archderm.1928.02380180188023.CrossRefGoogle Scholar
  32. 32.
    Klein P, Clark R. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol. 1999;135(12):1522–5. doi: 10.1001/archderm.135.12.1522.CrossRefPubMedGoogle Scholar
  33. 33.
    Eichenfield L, Hanifin J, Luger T, Stevens S, Pride H. Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol. 2003;49(6):1088–95. doi: 10.1016/s0190-9622(03)02539-8.CrossRefPubMedGoogle Scholar
  34. 34.
    Heddle R, Soothill J, Bulpitt C, Atherton D. Combined oral and nasal beclomethasone diproprionate in children with atopic eczema: a randomised controlled trial. BMJ. 1984;289(6446):651–4. doi: 10.1136/bmj.289.6446.651.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    La Rosa M, Musarra I, Ranno C, Maiello N, Negri L, del Giudice M, et al. A randomized, double-blind, placebo-controlled, crossover trial of systemic flunisolide in the treatment of children with severe atopic dermatitis. Curr Ther Res. 1995;56(7):720–6. doi: 10.1016/0011-393x(95)85143-7.CrossRefGoogle Scholar
  36. 36.
    Hundley J, Yosipovitch G. Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study. J Am Acad Dermatol. 2004;50(6):889–91. doi: 10.1016/j.jaad.2004.01.045.CrossRefPubMedGoogle Scholar
  37. 37.
    Ständer S, Böckenholt B, Schürmeyer-Horst F, Weishaupt C, Heuft G, Schneider T. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol. 2009;89(1):45–51. doi: 10.2340/00015555-0553.CrossRefPubMedGoogle Scholar
  38. 38.
    Ständer S, Schmelz M. Chronic itch and pain-similarities and differences. Eur J Pain. 2006;10(5):473–8. doi: 10.1016/j.ejpain.2006.03.005.CrossRefPubMedGoogle Scholar
  39. 39.
    Phan N, Bernhard J, Luger T, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63(4):680–8. doi: 10.1016/j.jaad.2009.08.052.CrossRefPubMedGoogle Scholar
  40. 40.
    Blakely K, Gooderham M, Papp K. Dupilumab, a monoclonal antibody for atopic dermatitis: a review of current literature. Skin Therapy. 2016;21(2):1–5.Google Scholar
  41. 41.
    Brenninkmeijer E, Spuls P, Lindeboom R, Van Der Wal A, Bos J, Wolkerstorfer A. Excimer laser vs. clobetasol propionate 0·05% ointment in prurigo form of atopic dermatitis: a randomized controlled trial, a pilot. Br J Dermatol. 2010;163(4):823–31. doi: 10.1111/j.1365-2133.2010.09858.x.CrossRefPubMedGoogle Scholar
  42. 42.
    Goeckerman W. The treatment of psoriasis. Northwest Med. 1925;24:229–31, 211.Google Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  1. 1.Georgetown University School of MedicineWashington, DCUSA
  2. 2.Department of DermatologyGeorge Washington UniversityWashington, DCUSA
  3. 3.Department of DermatologyChildren’s National Medical CenterWashington, DCUSA

Personalised recommendations